Islet Cell Autoimmunity in Women with Gestational Diabetes and Risk of Progression to Insulin-dependent Diabetes Mellitus

Mauricio, Daniel; Balsells, Montserrat; Morales, José Luis; Corcoy, Rosa; Puig‐Domingo, Manel; Leiva, Alberto de

doi:10.1002/(sici)1099-0895(199612)12:4<275::aid-dmr169>3.0.co;2-w

Cited by 18 publications

(17 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Obviously, higher figures are found in those studies assessing the prevalence of IAA in groups of women which included those under insulin treatment (not included in Table 2)26, 35. This issue was already dealt with in our previous review13. Interestingly, we have recently shown that 44% of women receiving insulin therapy for GDM develop insulin antibodies even after a short course of insulin treatment37.…”

Section: Islet Autoantibodies In Gdmmentioning

confidence: 95%

“…A similar profile of abnormalities associated with type 2 DM has been identified in women with GDM. However, there is a subset of women with GDM in which the profile of abnormalities resembles that of pre‐type 1 diabetic individuals and/or subjects with LADA13. The identification of markers of autoimmunity directed against beta‐cell antigens in a subgroup of gestational diabetic women lead to the initiation of investigations aiming at the characterisation of this subgroup of women.…”

Section: Introductionmentioning

confidence: 99%

“…In this update of our previous review13 we will focus on the new information that has since appeared, and the most relevant aspects and perspectives for the future of this topic.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Autoimmune gestational diabetes mellitus: a distinct clinical entity?

Mauricio

Leiva

2001

Diabetes Metabolism Res

Self Cite

View full text Add to dashboard Cite

This review gives an update of the present knowledge on what is defined here as autoimmune gestational diabetes mellitus (GDM). Autoimmune phenomena associated with type 1 diabetes mellitus (DM) can be detected in a subgroup of women with GDM. Islet autoantibodies are present in sera from women with GDM with variable frequency. Distinct phenotypic and genotypic features may be recognised in this subset of women with GDM, which are representative of a distinct clinical entity. Furthermore, these women are at increased risk of developing type 1 DM after pregnancy. However, the eventual progression of the autoimmune destruction of beta-cells in these subjects may follow different time-course patterns thus leading to variable forms of presentation of autoimmune DM. As a high-risk group for type 1 diabetes, women with previous autoimmune GDM may be candidates for potential immune intervention strategies.

show abstract

Section: Islet Autoantibodies In Gdmmentioning

confidence: 95%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Autoimmune gestational diabetes mellitus: a distinct clinical entity?

Mauricio

Leiva

2001

Diabetes Metabolism Res

Self Cite

View full text Add to dashboard Cite

show abstract

“…In the few reports that deal with this subject, the rate of IAA positivity in women with gestational diabetes seems to be similar to that of control subjects: 0% in both groups in the study of Damm et al (17). However, in a previous study, we found an IAA positivity rate of 11% in the women with gestational diabetes islet cell antibody (ICA) + subgroup, which is comparable to the rate in ICA + type I diabetic relatives (13). Despite treatment with HI, the rate of IA development after insulin therapy was high in both women with gestational diabetes and patients with type I diabetes.…”

Section: Conclusion-mentioning

confidence: 99%

“…The cutoff value for IA positivity in our laboratory (75 nlU/ml) was derived from the mean plus 3 SD (15 ± 20 nlU/ml) of a control group of 106 adults (normal distribution, pregnant and nonpregnant, no differences between both groups) (13). Nevertheless, the cutoff value for cord blood samples from nondiabetic pregnancies was higher: 131 nUI/ml (47 ± 28 nlU/ml).…”

Section: Insulin Antibody Assaymentioning

confidence: 99%

Insulin Antibody Response to a Short Course of Human Insulin Therapy in Women With Gestational Diabetes

et al. 1997

Self Cite

View full text Add to dashboard Cite

HI is immunogenic, and a short course of HI therapy induces IA in approximately 50% of women with gestational diabetes and 92% of type I diabetic patients. In women with gestational diabetes, insulin dose is slightly associated with IA titers. These IAs apparently cross the placenta. Fetal outcome does not differ according to the maternal IA status, and IAs disappear gradually after delivery but may remain positive for 2 years after delivery.

show abstract

Gestationsdiabetes – praktisches Vorgehen im klinischen Alltag

Lapaire

Huhn²,

Hartog³

et al. 2008

Therapeutische Umschau

View full text Add to dashboard Cite

Gestational diabetes is one of the most serious pregnancy associated disorders affecting up to 14% of all pregnant women. The increasing incidence also seen in Switzerland, has been due, among other factors, to the rise of maternal age and maternal body mass index. Due to its high incidence, its major impact on pregnancy outcome and the therpeutic approaches, an universal, instead of a selective screening is preferred. The clinical relevant key points are discussed in this review.

show abstract

Islet Cell Autoimmunity in Women with Gestational Diabetes and Risk of Progression to Insulin-dependent Diabetes Mellitus

Cited by 18 publications

References 50 publications

Autoimmune gestational diabetes mellitus: a distinct clinical entity?

Autoimmune gestational diabetes mellitus: a distinct clinical entity?

Insulin Antibody Response to a Short Course of Human Insulin Therapy in Women With Gestational Diabetes

Gestationsdiabetes – praktisches Vorgehen im klinischen Alltag

Contact Info

Product

Resources

About